Precision Medicine Articles & Analysis: Older

Having recently published a paper on gene.iobio, we are excited to announce a publication describing the clin.iobio tool as part of the Journal of Personalized Medicine's Special Issue on Precision Medicine in Clinical Practice. Clin.iobio has been developed by the iobio team in Prof. Gabor Marth's lab at the University of Utah, with collaboration from Frameshift. Clin.iobio has been built to ...

By Frameshift Labs, Inc.

For decades, data scientists and AI developers have typically followed the belief that “bigger is better” – the bigger the data set, the more analytical freedoms one has, and the more insights one gains. The AI industry still heavily relies on big data analytics, and for good reason – we need to feed AI large amounts of high quality, diverse data to ensure it works ...

By AiCure

The Covid-19 pandemic highlighted the disparity between those who succumbed to severe illness while others remained relatively unaffected, underscoring the urgent need to shift the healthcare industry’s focus from a one-size-fits-all approach to more personalised healthcare. Personalised medicine promises to transform healthcare with treatments tailored to a patient’s unique genetic ...

By Lifebit

Collaboration Announced Between Researchers at University of California Irvine and Population Diagnostics, Inc. at Rare Disease Event in Southern California The Spooner Girls Foundation , University of California, Irvine School of Medicine, (UCI) and Population Diagnostics, Inc. (PDx), announced today a collaborative research initiative focused on the NUBPL gene at the Spooner family’s ...

By Population Bio, Inc. a Precision Medicine Company

Introducing Beacon Biosignals: a neurotechnology company founded to develop machine learning-enabled EEG neurobiomarkers and accelerate precision medicine for any disease state affecting the brain Founded by MD/PhDs and engineers from Harvard and MIT, Beacon is propelled by the vision of a computing platform designed to scale the interrogation of large brain datasets with unprecedented ...

By Beacon Biosignals, Inc.

A growing number of governments, pharmaceutical companies and research organisations are choosing Lifebit for its secure, cutting-edge platform and visionary team. Lifebit is pleased to spotlight Brian Longo, who has joined as Lifebit’s Executive Strategic Advisor. Responsible for guiding the design and execution of Lifebit’s rapidly scaling operating models and processes, ...

By Lifebit

In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow. ...

By SOPHiA Genetics

Cancer is a heterogenous mixture of diseases characterized by, among other things, the abnormal, uncontrolled growth of cells derived from otherwise healthy tissues (Hanahan 2022). Although cancer cells sometimes grow into balls of cells and stop there (so-called benign tumors), often they gain the ability to disperse throughout the body, seed the growth of other tumors, disrupt the function of a ...

By Nautilus Biotechnology

In recent years, the field of biotechnology has seen groundbreaking advancements, with the integration of artificial intelligence (AI) into gene editing and therapy. AI-driven technologies have transformed the way we approach genetic modification and treatment, offering unprecedented opportunities for precision medicine and therapeutic interventions. One of the most significant applications of ...

By Creative Biogene

A large part of bacterial, archaeal, viral, and fungal microbial taxa consists of the human microbiome. While many of these microorganisms are commensal, some are harmful to humans and many are symbiotic. Our livelihoods are strongly intertwined with the microbes we allocate our bodies with, regardless of whether their appearance is advantageous, insignificant, or harmful. Over the past few ...

By CD Genomics

In recent years, the field of biotechnology has seen groundbreaking advancements, with the integration of artificial intelligence (AI) into gene editing and therapy. AI-driven technologies have transformed the way we approach genetic modification and treatment, offering unprecedented opportunities for precision medicine and therapeutic interventions. One of the most significant applications of ...

By Creative Biogene

Abstract The oncogene Ras and the tumor suppressor gene p53 are frequently co-mutated in human cancer and mutations in Ras and p53 can cooperate to generate a more malignant cell state. To discover novel druggable targets for cancers carrying co-mutations in Ras and p53, we performed arrayed, kinome focused siRNA and oncology drug phenotypic screening utilizing a set of syngeneic Ras mutant ...

By SEngine Precision Medicine

The next generation of positron emission tomography (PET) imaging agents will herald an age when PET will eclipse single photon emission computed tomog- raphy (SPECT) as the “go to” modality for molecular imaging. It will do so by enabling personalized medicine through precision diagnostics, the ability to be delivered cost-effectively in a manner with less radiation to patients, by ...

By Positron Corporation

TAILOR-PCI was a 7-year 5,300-patient clinical trial of precision medicine for cardiac stent patients, funded by Mayo Clinic and the National Institutes of Health (NIH). Genomadix’s FDA-cleared rapid RX CYP2C19 genotyping test was used to personalize antiplatelet therapy with clopidogrel or ticagrelor. The results were published on August 25, 2020 in the Journal of the American Medical ...

By Genomadix

Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...

By Tempus

ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 20201. At that time, based ...

By SOPHiA Genetics

Creative Biolabs, as a top-ranked solution provider of antibody-drug conjugate, scheduled a webinar about improved nuclear localization signal-therapeutics, which went live on January 21, 2022. Antibody-drug conjugate (ADC) has gained booming attention in the past 2021, with multiple international strategic purchases and breakthrough results of both preclinical and clinical trials. As a ...

By Creative Biolabs

SAN DIEGO--(BUSINESS WIRE)--Carlsmed, Inc. is announcing today that the firstaprevopatient specific spinal surgery has been successfully performed. Christopher Ames, M.D., director of spinal tumor and spinal deformity surgery at UC San Francisco Medical Center, assisted by Patrick Maloney, M.D., performed this landmark surgical procedure. “Carlsmed’s aprevofamily of devices represent ...

By Carlsmed, Inc.

In the vast realm of drug discovery, the fusion of computational prowess and intricate molecular details has given birth to the revolutionary field of protein-small molecule docking. This innovative computational method delves deep into the complex molecular interactions between proteins and small molecules, paving the way for breakthrough advancements in therapeutic approaches and the era of ...

By CD ComputaBio

The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit’s Federated Trusted Research Environment software, Lifebit CloudOS, within Denmark's national supercomputing center. LONDON, UK - 28 April 2022 – Lifebit, whose leading technology enables secure analysis over sensitive datasets for researchers and interconnects such large patient cohorts ...

By Lifebit